US Bancorp’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.32M Sell
5,330
-298
-5% -$203K ﹤0.01% 740
2026
Q1
$4.35M Buy
5,628
+81
+1% +$62K 0.01% 637
2025
Q4
$4.28M Sell
5,547
-155
-3% -$105K 0.01% 645
2025
Q3
$3.21M Buy
5,702
+215
+4% +$122K ﹤0.01% 727
2025
Q2
$2.88M Sell
5,487
-858
-14% -$479K ﹤0.01% 749
2025
Q1
$4.02M Buy
6,345
+279
+5% +$192K 0.01% 635
2024
Q4
$4.32M Buy
6,066
+1,078
+22% +$905K 0.01% 625
2024
Q3
$5.24M Sell
4,988
-175
-3% -$195K 0.01% 573
2024
Q2
$5.43M Buy
5,163
+153
+3% +$148K 0.01% 557
2024
Q1
$4.82M Buy
5,010
+69
+1% +$65.6K 0.01% 591
2023
Q4
$4.34M Buy
4,941
+310
+7% +$255K 0.01% 606
2023
Q3
$3.81M Buy
4,631
+59
+1% +$46.4K 0.01% 610
2023
Q2
$3.29M Sell
4,572
-536
-10% -$413K 0.01% 652
2023
Q1
$4.2M Buy
5,108
+168
+3% +$127K 0.01% 590
2022
Q4
$3.56M Sell
4,940
-843
-15% -$622K 0.01% 630
2022
Q3
$3.98M Buy
5,783
+74
+1% +$46.6K 0.01% 561
2022
Q2
$3.38M Sell
5,709
-289
-5% -$188K 0.01% 630
2022
Q1
$4.19M Buy
5,998
+37
+0.6% +$23.4K 0.01% 613
2021
Q4
$3.77M Buy
5,961
+37
+0.6% +$22.7K 0.01% 670
2021
Q3
$3.58M Sell
5,924
-187
-3% -$116K 0.01% 661
2021
Q2
$3.41M Buy
6,111
+93
+2% +$47.1K 0.01% 693
2021
Q1
$2.85M Buy
6,018
+626
+12% +$305K 0.01% 722
2020
Q4
$2.6M Buy
5,392
+831
+18% +$449K 0.01% 712
2020
Q3
$2.55M Buy
4,561
+1,302
+40% +$789K 0.01% 667
2020
Q2
$2.03M Sell
3,259
-252
-7% -$143K 0.01% 716
2020
Q1
$1.71M Sell
3,511
-239
-6% -$98.6K 0.01% 714
2019
Q4
$1.41M Buy
3,750
+94
+3% +$31.6K ﹤0.01% 905
2019
Q3
$1.01M Sell
3,656
-64
-2% -$18.9K ﹤0.01% 1022
2019
Q2
$1.16M Sell
3,720
-1,719
-32% -$572K ﹤0.01% 1009
2019
Q1
$2.23M Buy
5,439
+13
+0.2% +$5.35K 0.01% 726
2018
Q4
$2.03M Sell
5,426
-617
-10% -$226K 0.01% 734
2018
Q3
$2.44M Buy
6,043
+66
+1% +$25.1K 0.01% 731
2018
Q2
$2.06M Sell
5,977
-320
-5% -$100K 0.01% 791
2018
Q1
$2.17M Buy
6,297
+133
+2% +$46.3K 0.01% 762
2017
Q4
$2.32M Buy
6,164
+599
+11% +$243K 0.01% 742
2017
Q3
$2.49M Buy
5,565
+420
+8% +$200K 0.01% 708
2017
Q2
$2.53M Buy
5,145
+862
+20% +$377K 0.01% 680
2017
Q1
$1.66M Sell
4,283
-152
-3% -$56.3K 0.01% 849
2016
Q4
$1.63M Buy
4,435
+231
+5% +$87.8K 0.01% 841
2016
Q3
$1.69M Sell
4,204
-203
-5% -$81.4K 0.01% 792
2016
Q2
$1.54M Buy
4,407
+431
+11% +$166K 0.01% 807
2016
Q1
$1.43M Buy
3,976
+1
+0% +$412 0.01% 813
2015
Q4
$2.16M Buy
3,975
+340
+9% +$184K 0.01% 678
2015
Q3
$1.69M Buy
3,635
+429
+13% +$230K 0.01% 751
2015
Q2
$1.64M Sell
3,206
-1,713
-35% -$836K 0.01% 803
2015
Q1
$2.22M Buy
4,919
+1,346
+38% +$570K 0.01% 686
2014
Q4
$1.47M Buy
3,573
+45
+1% +$17.7K 0.01% 823
2014
Q3
$1.27M Buy
3,528
+32
+0.9% +$10.7K 0.01% 874
2014
Q2
$987K Buy
3,496
+230
+7% +$68.2K ﹤0.01% 1007
2014
Q1
$980K Buy
3,266
+991
+44% +$305K ﹤0.01% 990
2013
Q4
$626K Buy
2,275
+722
+46% +$208K ﹤0.01% 1175
2013
Q3
$485K Buy
1,553
+747
+93% +$196K ﹤0.01% 1251
2013
Q2
$181K Buy
+806
New +$188K ﹤0.01% 1695

Other funds holding REGN

US Bancorp's REGN Position: Q2 2026 in Review

US Bancorp reduced its Regeneron Pharmaceuticals (REGN) stake by 5.3% in Q2 2026, selling an estimated $203K and leaving 5,330 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #740.

US Bancorp first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.43M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • US Bancorp held 5,330 shares of Regeneron Pharmaceuticals worth $3.32M as of Q2 2026.
  • US Bancorp sold 298 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $203K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #740 holding.
  • US Bancorp first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • US Bancorp's Regeneron Pharmaceuticals position peaked at $5.43M in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.